Cure My Disease

Don't miss your cure!

 Log in / Sign up

Arthritis drug shows promise against pancreatic cancer in early trial

NCT ID NCT06454383

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests whether adding leflunomide, a drug used for rheumatoid arthritis, to standard chemotherapy (gemcitabine) is safe for people with advanced pancreatic cancer that cannot be removed by surgery. About 19 participants will receive the combination to find the best dose and check for side effects. The goal is to see if this approach can make chemotherapy work better without causing more harm.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
leflunomide (a rheumatoid arthritis drug) combined with gemcitabine (chemotherapy)
What this could lead to
If it works, this could point toward a more effective chemotherapy combination for advanced pancreatic cancer, potentially improving survival and quality of life.
What could go wrong
This is a very early phase 1b trial with only 19 patients, focused on safety and dosing. The combination may not prove effective or could cause unexpected side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC ADENOCARCINOMA STAGE III PANCREATIC CANCER AJCC V8 STAGE IV PANCREATIC CANCER AJCC V8 UNRESECTABLE PANCREATIC DUCTAL ADENOCARCINOMA

Contacts and locations

Locations

  • City of Hope Medical Center

    RECRUITING

    Duarte, California, 91010, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.